Bayer Report Result of Nubeqa (darolutamide) + ADT in P-III ARAMIS Study for Non-Metastatic Castration-Resistant Prostate Cancer

 Bayer Report Result of Nubeqa (darolutamide) + ADT in P-III ARAMIS Study for Non-Metastatic Castration-Resistant Prostate Cancer

Bayer Report Result of Nubeqa (darolutamide) + ADT in P-III ARAMIS Study for Non-Metastatic Castration-Resistant Prostate Cancer

Shots:

  • The P-III ARAMIS study involves assessing of Nubeqa (600mg, bid) + ADT vs PBO + ADT in 1,509 patients in a ratio (2:1) with nmCRPC who were receiving a concomitant GnRH analog or had a bilateral orchiectomy
  • The P-III ARAMIS study resulted in meeting its 1EPs i.e, improvement in MFS (40.4 vs 18.4mos.)
  • Nubeqa is an androgen receptor inhibitor (ARi) binding it with high affinity, thus inhibiting the growth of prostate cancer cells and is an approved therapy in the US, Brazil and Japan. Bayer has filed for its approval in the EU

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: Bayer

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post